Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Tu

Hospice and Palliative Medicine Columbus, OH Medical Doctor

NPI 1710109905 CMS profile 122408

543 Taylor Ave, 1St Floor, Columbus, OH 43203

Open in the dashboard

General payments

$4,888

131 records reported · program years 2019–2025

Research payments

$920

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Tu of Columbus, OH is reported in the CMS Open Payments database as having received $4,888 across 131 general payments and $920 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $633 15
2024 General $915 25
2023 General $585 26
2022 General $724 21
2021 General $704 10
2021 Research $230 1
2020 General $495 12
2020 Research $690 2
2019 General $832 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Tu
  • Ohio median
  • Middle half of Ohio
  • National median

In program year 2025, general payments to Joseph Tu were reported at $633. Among 40,289 Ohio profiles paid that year, the median was $159 and the middle half received between $47 and $569.

Show as a table
Year Joseph Tu Ohio median Middle half National median
2019 $832 $166 $50–$652 $163
2020 $495 $110 $33–$367 $114
2021 $704 $125 $35–$432 $132
2022 $724 $141 $41–$498 $149
2023 $585 $150 $43–$522 $160
2024 $915 $153 $45–$543 $164
2025 $633 $159 $47–$569 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,524 58 payments
  2. Abbott Laboratories $528 13 payments
  3. Nevro Corp. $524 7 payments
  4. Saluda Medical Americas, Inc. $521 10 payments
  5. Nalu Medical, Inc. $355 8 payments
  6. Medtronic USA, Inc. $354 5 payments
  7. Pfizer Inc. $252 6 payments
  8. Averitas Pharma Inc. $161 3 payments
  9. Biodelivery Sciences International, Inc. $146 3 payments
  10. Globus Medical, Inc. $105 1 payment
  11. Other $418 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,888 131 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $1,242 54 payments
  2. Evoke $521 10 payments
  3. Proclaim Family of SCS IPGs $402 9 payments
  4. Nalu Neurostimulation System $355 8 payments
  5. Omnia $342 5 payments
  6. INTELLIS Spinal Cord Neurostimulation $291 3 payments
  7. Senza $182 2 payments
  8. Qutenza $161 3 payments
  9. INTELLIS Spinal Cord Neurostimulation $148 2 payments
  10. Vanta $128 1 payment
  11. Other $1,086 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic USA, Inc. $690 2 payments
  2. Medtronic, Inc. $230 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

6,172

Median for Pain Management: 951

Drug cost

$335,918

Median for Pain Management: $26,034

Branded share of claims

30.1%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Percocet Oxycodone Hcl/Acetaminophen Brand 11 $53,698
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 946 $28,362
Oxycontin Oxycodone Hcl Brand 34 $27,165
Buprenorphine Generic 52 $19,923
Belbuca Buprenorphine Hcl Brand 39 $19,629
Fentanyl Generic 96 $17,478
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 502 $15,187
Oxycodone Hcl Generic 735 $15,000
Movantik Naloxegol Oxalate Brand 33 $13,611
Lidocaine Generic 71 $12,779

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$139,372

Of which drugs: $5,874

Medicare patients

486

Average age 71

Services billed

4,144

302 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Depression 46%
Ischemic heart disease 38%
Diabetes 36%
Chronic kidney disease 27%
COPD 24%
Osteoporosis 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospice and Palliative Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record